STOCK TITAN

Exact Sciences to participate in June investor conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

  • William Blair 42nd Annual Growth Stock Conference, Chicago
    Presentation on Monday, June 6, 2022 at 3:40 p.m. ET

  • Jefferies Healthcare Conference, New York
    Fireside Chat on Wednesday, June 8, 2022 at 1:00 p.m. ET

  • Goldman Sachs 43rd Annual Global Healthcare Conference, Rancho Palos Verdes
    Fireside Chat on Monday, June 13, 2022 at 6:20 p.m. ET

  • Nephron Liquid Biopsy Innovation Symposium, virtual
    Fireside Chat on Tuesday, June 21, 2022 at 11:00 a.m. ET

The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com.

About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-june-investor-conferences-301556503.html

SOURCE Exact Sciences Corporation

Exact Sciences Corp

NASDAQ:EXAS

EXAS Rankings

EXAS Latest News

EXAS Stock Data

11.41B
179.56M
1.01%
89.38%
3.49%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States of America
MADISON

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com